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Abstract
Background: Liver cancer makes up a huge percentage of cancer mortality worldwide. Irreversible electroporation (IRE) is a
relatively newminimally invasive nonthermal ablation technique for tumors that applies short pulses of high frequency electrical energy
to irreversibly destabilize cell membrane to induce tumor cell apoptosis.
Methods: This review aims to investigate the studies regarding the use of IRE treatment in liver tumors and metastases to liver. We
searched PubMed for all of IRE relevant English language articles published up to September 2016. They included clinical trials,
experimental studies, observational studies, and reviews. This review manuscript is nothing with ethics issues and ethical approval is
not provided.
Results: In recent years, increasingly more studies in both preclinical and clinical settings have been conducted to examine the
safety and efﬁcacy of this new technique, shedding light on the crucial advantages and disadvantages that IRE possesses. Unlike the
current leading thermal ablation techniques, such as radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation,
IRE requires shorter ablation time without damaging adjacent important vital structures.
Conclusion: Although IRE has successfully claimed its valuable status in the ﬁeld of hepatic cancer treatment both preclinical and
clinical settings. In order to systemically test and establish its safety and efﬁcacy for clinical applications, more studies still need to be
conducted.
Abbreviations: CT = computed tomography, HCC = hepatocellular carcinoma, IRE = irreversible electroporation, LRFS = local
recurrence free survival, MWA = microwave ablation, RFA = radiofrequency ablation.
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1. Introduction primary liver cancers, hepatocellular carcinoma (HCC) is theLiver cancer can be divided into 2 categories based on the primary
tumor site: primary liver cancer and metastatic cancer to liver
(liver metastases). Primary liver cancer is the 3rd leading cause of
cancer mortality worldwide[1] and the 7th leading cause of
cancer-related death in the United States.[2] Among the types ofEditor: Kavindra Nath.
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1predominant histologic form[3] and has an incidence similar to
the US liver cancer mortality rate, indicating a poor prognosis for
HCC patients.[4] According to the data from Surveillance,
Epidemiology, and End Results Program of National Cancer
Institute, both the HCC incidence rate and the US liver cancer
mortality rate increased over recent years, from 3.1 to 5.1 per
100,000 persons and from 3.3 to 4.0 per 100,000 persons,
respectively.[5] Furthermore, survival rate in patients with
advanced HCC is not signiﬁcantly improved by systemic
chemotherapy.[6,7] Only 20% to 30% of patients are eligible
candidates for surgical tumor resection when they are diagnosed.
Safer and more efﬁcient procedures are desperately needed for
liver tumors and metastases treatment.[8] This review compares
irreversible electroporation (IRE) with other traditional ablation
techniques and includes research studies in both preclinical and
clinical settings published in recent years focused on investigating
safety and/or efﬁcacy of IRE technique, aiming to summarize
these studies to provide an update of IRE application and
improve the clinical practice of this new technique.
We searched PubMed for all of IRE relevant English language
articles published up to September 2016. This review manuscript
is nothing with ethics issues and ethical approval is not necessary.2. IRE and other local ablation techniques
Local ablation techniques have been crucial and useful for
treating benign or malignant tumors in the past several decades.
Lyu et al. Medicine (2017) 96:17 MedicinePartial liver resection or liver transplantation is still the most
preferred method for treating malignant tumors for its potential
of curing the cancer. However, the application of liver resection
or transplantation is largely affected by several factors including
patient’s general condition, liver function reserve, and tumor
stage and so on. Also, it is constrained by the location of the
tumor. In this case, few patients can be eligible candidates for this
primary treatment. IRE is a comparatively new minimally
invasive nonthermal ablation therapy for hepatic tumor where
high frequency electrical energy is applied in short pulses to ablate
tissue.[9,10] Electroporation induces increased permeability of cell
membrane.[11,12] This can lead to an abnormal transmembrane
electrical potential across the plasma membrane which will
irreversibly open the plasma membrane leading to cell apopto-
sis.[13,14] However, while electroporation technology has been
utilized for decades,[15–17] IRE is still an emerging ﬁeld in clinical
application.
In addition to IRE, several other alternatives have been
developed for ablating liver cancer, such as cryoablation,
radiofrequency ablation (RFA), and microwave ablation
(MWA). Every technique has been proven effective under certain
circumstances and possesses its own advantages and disadvan-
tages. Cryoablation freezes malignant tissue with a low
temperature probe, which can be guided accurately by
intraoperative ultrasonography and thermally monitored pre-
cisely with thermocouple.[18] However, it is difﬁcult to use
cryoablation when the lesion is close to large vessels because the
relative heat of circulating blood may warm cryoprobe and
decrease treatment efﬁcacy.[18] Also, cryoablation can cause
variable damage at the margin of ablation zones and injury to
adjacent structures.[19] RFA is another popular local ablation
technique that thermally destroys the malignant tissue by placing
a small electrode into the tumor to deliver directed radio-
frequency energy. MWA is a form of thermal ablation used in
interventional radiology to treat cancer. It uses electromagnetic
waves in the microwave energy spectrum to produce tissue-
heating effects. RFA and MWA are both widely used techniques,
and in both techniques, the generated heat is difﬁcult to control
due to thermal ﬂuctuation from blood circulation which affects
the local heat.[18,20,21]
Unlike the other alternative techniques, IRE requires minimal
energy input into the system and can induce cell death in a
nonthermal way, giving IRE an unique advantage in treatment of
liver cancer.[19,22,23] Typically, RFA procedures run in 375 to
500kHz and MWA functions at 915MHz or 2.45GHz, while
cryoablation requires cooling tumors to cytotoxic temper-
atures.[23,24] Compared to other alternatives, IRE only applies
several series of electrical pulses (typically 90 pulses) ranging
from 1500 to 3000V. The nonthermal electrical characteristic of
IRE prevents collateral damage to other tissues, such as vessels,
ducts, and nerves, which often occur in thermal ablation
techniques.[25,26] Furthermore, IRE creates a sharp edge between
the treated and untreated tissues, thus providing a higher regional
speciﬁcity in ablation which allows relatively easier monitoring
and controlling.[27] In addition, IRE requires shorter time to
operate than other traditional ablation techniques because of its
nonthermal characteristic, making it a more efﬁcient technique
than others. Recently, Tam and Abdelsalam[28] evaluated the
intratumoral uptake of nanoparticles used in combination with
IRE or RFA in rabbit VX2 models, they found the nanoparticles
in the tumor was most intense after RFA at 1 hour time point.
However, the uptake of nanoparticles increased at 18-hour time
point in IRE group, higher than RFA group, whose uptake2decreased during the time range. This study suggested that IRE
might have ability to accelerate the cellular internalization of
molecules.3. IRE of hepatic tumors in preclinical settings
In recent years, more and more animal models have been built to
evaluate the safety and efﬁcacy of IRE. Different approaches were
created to test the effects of different parameter settings on animal
models. Summary of recent animal liver models of IRE in
preclinical settings is shown in Table 1.[25,29–34]
In 2012, Lee and Tafti[33] corroborated the safety and efﬁcacy
of IRE in treating large tumor models in vivo by a rabbit model.
They implanted VX2 tumors in 35 New Zealand White Rabbits
and divided them into control, single IRE (IRE-S), and multiple
IRE (IRE-M) 3 groups. The rabbits in IRE-S group underwent
single IRE application, and those in IRE-M group were treated
with multiple IRE applications. Before IRE treatment, the
intrahepatic VX2 tumors were allowed to grow up to 1 to 1.5
cm. The mean longest diameter of ablation zones in IRE-S group
was 3.6cm and in IRE-M group was 3.9cm. Contrast-enhanced
computed tomography (CT) scans were performed on all the
animals before the procedure at 24hours, 3 days, and 21 days
after treatment. Outcomes from both IRE-S and IRE-M group
showed a signiﬁcant decrease in tumor volume compared with
control group. Furthermore, complete ablation of tumor was
observed in IRE-M group 21 days after procedure, indicating a
promising efﬁcacy of IRE. No complication was observed in the
experiment either during or after IRE sessions. Lee and Prieto[25]
also created another animal liver model in 16 Yorkshire pigs,
which demonstrated IRE as a safe and effective ablative method.
Fifty-ﬁve ablations were performed with real-time monitoring
with ultrasound and followed by ultrasound, MRI, and CT. The
mean longest diameter of the ablation zones was 3.4± .3cm.
Tumor cell death was observed with no complication in any of
16 animals and with full preservation of periablative zone
structures including blood vessels, bile ducts, and neighboring
tissues. The treatment areas were sharply demarcated, and areas
of complete cell death stained positive for apoptotic markers
(TUNEL, BCL-2 oncoprotein), suggesting involvement of the
apoptotic process in the pathophysiology of cell death caused by
IRE. In another swine model built by Charpentier et al,[32] 16
liver ablations and 4 ablations in the liver hilum were performed
in 8 healthy pigs using 2monopolar electrodes spaced 2cm apart.
The longest diameter of ablation zones ranged from 2.95±0.31
cm to 4.45±0.07cm. Hemorrhagic necrosis of the hepatocytes in
the ablation zone were found with no evidence of heat sink and
no major complication. Bile ducts, portal veins, and hepatic
arteries were well-preserved. According to the ablation results of
these studies, IRE may have the potential to be superior to
conventional thermal ablation for the treatment of small,
unresectable liver tumors.
In addition to swine models, 30 Sprague-Dawley rat models
were built by Guo et al[29] to examine the efﬁcacy of IRE. In this
model, signiﬁcant differences in tumor size was found between
the treated and untreated groups of HCC rat models with no
postoperative complications in the treated group (Fig. 1). MR
images showed a signiﬁcant tumor size reductionwithin 15 days
posttherapy, and histology correlation studies showed a
clear progression from poorly differentiated viable hepatoma
tissue pretherapy to extensive tumor necrosis and complete
tumor regression in 9 of 10 treated rats 7 to 15 days after
treatment.
Table 1
Summary of recent animal liver models of IRE in preclinical settings.
Year Authors Animal model Number Voltage, V Duration, ms Outcomes
2010 Guo et al[29] Rat 30 2500 100 Showed potential efﬁcacy of IRE as an ablation technique for the
treatment of HCCHCC
2010 Zhang et al[30] Rat 18 1000/1500/2500 100 Showed MR imaging permits immediate depiction of ablated tissue
zones for monitoring of IRE ablation proceduresNormal
2010 Lee et al[25] Pig 16 2000–3000 100 Examined the safety and efﬁcacy of IRE and found complete tissue
death without complicationNormal
2011 Guo et al[31] Rat 15 500–1000 100 Demonstrated IR-prepared contrast-enhanced MR imaging could be
used to quantitatively measure IRE ablation zones in the liverNormal
2011 Charpentier et al[32] Pig 8 2500–3000 100 Demonstrated IRE could be performed safely efﬁciently in liver hilum
for liver tissue ablationNormal
2012 Ben-David et al[53] Pig 25 2250–3000 50–100 Proved zones of tissue destruction could be predictable by adjusting
different parameters in IRE sessionsNormal
2012 Lee et al[33] Rabbits 20 2500 100 Examined the safety and efﬁcacy of IRE and validated the potential
of IRE as a clinically translatable treatmentHCC
2014 Zhang et al[34] Rat
HCC
24 2500 100 Found IRE induced rapid changes on imaging tools, suggesting the
possibility of delineating ablation zones from the unablated
surrounding parenchyma
HCC=hepatocellular carcinoma, IRE= irreversible electroporation.
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To date, 9 published case series have evaluated the safety and
efﬁcacy of IRE on human liver tumors. All of them adopted the
NanoKnife system (AngioDynamics, New York), which
consists of a footswitch, a control panel with a screen and a
cardiac synchronizer, and a direct current generator connected
with unipolar or bipolar needle electrodes. Table 2 shows
summary of recent IRE studies on liver tumor treatment in
clinical settings.[35–42]
In 2010, Ball et al[43] published a clinical trial report of IRE on
evaluating the complications associated with IRE procedure
which is the ﬁrst report of IRE intervention in human subjects.
They found IRE to be an encouraging new technique and most
importantly, it spared adjacent tissues with no vascular damage.
All complications were manageable and largely predicable.
Later, a single-center prospective nonrandomized cohort study
was published by Thomson et al in 2011,[44] which included 38
patient volunteers with advanced liver, kidney, or lung
malignancy. Clinical examination, biochemistry, and CT scans
were obtained before, immediately after, 1 month after, and 3
months after IRE to examine the treated area. A total of 63 IRE
ablations of liver tumors were performed in 25 patients, and
immediate postprocedure CT scans showed rim enhancement
with no enhancement of the ablated areas. Subsequent 1- and 3-
month follow-up CT scans showed nonenhancement in both the
ablated areas and the rims. Fifteen out of the 18 targeted tumors
were successfully ablated in HCC patients. The IRE response rate
reached 50% in liver metastases group. However, progressive
disease was found in all individuals in this group and all
metastases larger than 5cm showed no response compared to
control group. According to this study, Thomson found IRE to be
safe for human clinical use when ECG-synchronized delivery was3used. The author also suggested that there was no evidence of
major vessel or bile duct injury when these structures were
included in the IRE procedure zones.
A retrospective review study of patients treated with a total 31
separate IRE procedures over a period of 10months was reported
by Kingham et al.[45] The study included 28 patients with 65
tumors ranging from 0.5 to 5cm with a median of 1cm. The
majority of patients had colorectal cancer liver metastases (75%),
and HCC patients made 7% of the study population. Contrast-
enhanced CT scans or MRI was performed in the immediate
perioperative period at 1 to 3 months and 6 months. Overall,
there were 3 local recurrences and 1 tumor with persistent disease
– a combined local failure rate of 7.5%. Within the study, 41
tumors were located within 1cm of a major hepatic vein or portal
pedicle. Complications included 1 case of intraoperative
arrhythmia and 1 case of postoperative portal vein thrombosis.
The mortality rate was 3% with no treatment-associated
mortality. As a result, the authors concluded that IRE technique
was a safe treatment option for patients with perivascular
malignant hepatic tumors.
Similar results were found by Cannon et al,[46] who published a
study representing a multiinstitutional prospective registry of
44 patients undergoing 48 IRE procedures near vital structures in
a period of 2 years for liver tumors including 20 colorectal
metastases, 14 HCCs, and 10 other metastases. The study was
speciﬁcally focused on the tumors which were in proximity to
vital structures. Patients were followed up at the time of discharge
or within 2 weeks of IRE procedure for safety consideration and
then at 3-month intervals with CT or MRI evaluations. Initial
success was achieved in 100% of the procedures, with an overall
local recurrence free survival (LRFS) rate of 97.4%, 94.6%, and
59.5% at 3, 6, and 12 months, respectively. In addition, a trend
toward higher recurrence rates was found for tumors larger than
Figure 1. MRI images in axial and coronal orientations along with corresponding pathologic H&E slide images for an untreated 15-d end point control rat (A) and a
15-d post-IRE treatment rat (B).[29] A signiﬁcant reduction of tumor size in IRE-treated animal (B) is shown compared to the untreated rat (A). Arrows indicate tumor
positions. H&E pathology slides showed 70% viable tissue within the untreated tumor (A) and completed tumor regression within the IRE-treated rat (B). Scatter plot
(C) shows the percentage of viable tumor tissue for 6 rats at baseline control interval (group 1), 6 untreated control rats following a 15-d growth period after original
baseline scan (group 2), and 6 IRE-treated rats following the same 15-d growth period (group 3). Box plots (D) show the Dmax
∗
increase (left) and Cmax
∗
increase
(right) for 15-d follow-up animals in untreated control group 2 and IRE-treated group 3. Dmax and Cmax increase for group 2 rats were signiﬁcantly greater than Dmax
and Cmax increase for group 3 rats (P= .004 for both comparisons using nonparametric Mann–Whitney U test).
∗
Dmax, along the orientation bearing the largest
tumor diameter;
∗
Cmax, the cross-product of the maximum lesion diameter Dmax and largest diameter measured perpendicular to Dmax. IRE= irreversible
electroporation, MRI=magnetic resonance imaging.
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a slight difference between the surgical and percutaneous
approaches of IRE was observed 3 and 6 months postprocedure.
There were 9 adverse events after 5 procedures. Three of these 9Table 2
Summary of recent IRE studies on liver tumor treatment in clinical s
Year Authors Patients Tumor IRE sessions Tumor size, mm
2011 Thomson et al[35] 25 N/A 63 10–80 1
2012 Kingham et al[36] 28 65 31 5–50 1
2013 Cannon et al[37] 44 44 48 11–110 1
2014 Hosein et al[38] 28 58 36 12–70
2015 Cheng et al[39] 6 6 6 6–26 1
2015 Sugimoto et al[40] 5 6 6 11–28 1
2016 Padia et al[41] 20 N/A N/A 10–33 1
2016 Niessen et al [42] 34 65 N/A 2–71
HCC=hepatocellular carcinoma, IRE= irreversible electroporation, LRFS= local recurrence free survival,
4adverse events including neurogenic bladder, abdominal pain,
and ﬂank pain may have been procedure related. All complica-
tions resolved within 30 days, and there were no treatment-
related deaths.ettings.
Voltage, V Duration, ms
Complete ablation rate LRFS
HCC Metastases Rate Time
500–3000 70 .83 .50 N/A N/A
500–3000 70 N/A N/A .93 6 months
500–3000 100 1.00 1.00 .95 6 months
N/A N/A N/A .97 .79 2 years
500–3000 90–100 1.00 N/A 1.00 3–17 months
500–1800 70 .83 N/A 1.00 244±55 days
500–3000 20–100 .90 N/A 1.00 1 year
1500 90 1.00 .95 .80 6 months
N/A=not available.
Figure 2. MR images of HCC after IRE in a 63-year-old man.[49] Baseline axial (A) and coronal (B) gadolinium contrast-enhanced T1-weighted MR images obtained
in the arterial phase show a 2-cm HCC lesion (arrow) in the right hepatic lobe adjacent to the right portal vein. (C) Unenhanced coronal CT image obtained after
percutaneous IRE shows 3 electrodes in a parallel conﬁguration. (D) T2-weighted MR image obtained 24hours after IRE shows a large ablation zone (arrow) of
diffuse increased signal intensity. (E) Unenhanced T1-weighted MR image obtained 24hours after IRE shows slight hyperintensity of the ablated tumor with
associated decreased signal intensity in the ablative margin (arrow). (F) T1-weighted MR image obtained in the arterial phase 1 day after IRE shows marked
persistent enhancement of the ablative margin (arrow). The rumor itself demonstrates no enhancement. (G) T2-weighted MR image obtained 30 days after IRE
shows amarked reduction of the ablation zone (arrow). (H) Unenhanced T1-weightedMR image obtained 30 days after IRE shows that the increased signal intensity
of the tumor (arrow) persists. The size of the tumor decreased compared with day 1 after IRE. (I) T1-weighted MR image obtained in the arterial phase 30 days after
IRE shows a substantial decrease in the size of the ablation zone compared with day 1 and thinning of the ablative margin (arrow). Unenhanced (J) T2- and (K) T1-
weighted MR images obtained 120 days after IRE show further involution of the ablation zone and persistent slightly increased signal intensity of the tumor (arrow).
(L) MR image obtained in the arterial phase shows a lack of enhancement in the entire ablation zone. CT=computed tomography, HCC=hepatocellular carcinoma,
IRE= irreversible electroporation, MR=magnetic resonance.
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Bonilla[47] analyzed 29 patients (28 evaluable) who underwent 36
IRE sessions on 58 tumors for the management of colorectal liver
metastasis between March 2010 and February 2013. All patients
were assessed by CT scan immediately after IRE treatment, most
had subsequent CT scans after 30 days according to patients’
condition. No biliary strictures, vessel stenosis, thrombosis, or
shunting within or near the treatment zones were observed in the
CT scan results. Two adverse events related to IRE procedures
were found in 2 patients (7%) including 1 case of ventricular
arrhythmia and 1 case of atrial ﬁbrillation; both resolved
without sequelae. According to the study, LRFS reached 79% at
the 2-year time point. However, all patients (n=19, 100%)
showed progressive disease within 2 years.
Cheng et al[48] published a similar retrospective study in the
following year focusing on 6 HCC patients who underwent a
total of 6 IRE procedures before liver transplant. All tumors
showed a complete response on follow-up cross-sectional
imaging performed at 1 month and every 3 months until liver
transplant. Complete pathologic necrosis was observed in 5 of 6
treated tumors with sharp edges and well-preserved bile duct.
Recently Padia and Yeung[49] published a retrospective study
with 20 HCC patients treated with IRE which aimed to assess the
postprocedure ﬁndings of IRE with MRI. The study reported a
trend of decreasing signal intensity in the peripheral ablation zone
on both T2-weighted (P= .01) and T1-weighted (P< .08) images
acquired on postprocedure day 1, 30, and every 90 days
thereafter. Complete response was observed in 18 patients (90%)
with the other 2 patients showing a partial response (Fig. 2).
In 2015, Sugimoto and Kobayashi[50] conducted a prospective
clinical trial to assess the safety of IRE in Japan including 5
patients with 6 HCCs enrolled. Within the study, 5 of the 6
tumors were successfully treated and no local recurrence at 244±
55 days of follow-up. No procedure-related complications were
seen during or after IRE intervention but an increase of 78 and 36
mmHg in systolic and diastolic blood pressure were observed as a
minor complication.
In another prospective single-center study, Niessen and
Pregler[51] found promising results on the therapeutic efﬁcacy
of IRE treatment for hepatic tumors. The study included 65
malignant tumors in 34 patients, of which 33 were HCCs, 22
were colorectal cancer metastasis, 5 were cholangiocellular
carcinoma, 3 were neuroendocrine cancer metastasis, and 2 were
testicular cancer metastasis. The primary follow-up imaging was
performed within 24 hours via both contrast-enhanced CT scans
and MR imaging after the IRE procedure. Twelve tumors were
treated with a 2nd IRE procedure for incomplete ablation and
local recurrence observed by follow-up imaging. LRFS was
87.4%, 79.8%, and 74.8% at 3, 6, and 12months. However, the
complication rate was 27.5% with 6 major complications
including 1 diffuse intraperitoneal bleeding, 1 partial thrombosis
of the portal vein, and 4 liver abscesses. The high complication
rate drew signiﬁcant concerns to its safety.5. Discussion
As discussed above, IRE processes its own advantages especially
including avoiding the heat sink and sparing vital structures
adjacent to tumor. The tumor ablation efﬁcacy is promising,
especially for those tumors smaller than 5cm. Vital structures
were all well-preserved in the studies although they were really
close to the ablated area.6However, IRE is still not the ﬁrst preferred choice among the
various ablation procedures for HCC patients due to its
limitations. In most situations, only patients who have limited
volume hepatic tumor and who are not candidates for liver
transplantation or other thermal ablation surgeries will be
enrolled in IRE treatment. As one of its shortcomings, IRE always
requires general anesthesia and adequate neuromuscular block-
age for its potential to cause muscle stimulation from high current
during the procedure. Another important shortcoming of IRE is
the inability to completely ablate large tumors, especially those
larger than 5cm, without repetition or repositioning the
electrodes, which limits the number of qualiﬁed candidates.[52]
In addition, IRE can cause unintended injury to other structures
when electrodes are placed. Ball et al[43] reported 3 instances of
pneumothorax during their study. One of these cases occurred
after transabdominal placement of electrodes in the liver. No
treatment was required for the other 2 cases and none of the 3
cases required urgent treatment. Also, the same group found 3
cases of pneumothorax in another clinical trial published in
2011.[44] One of them was caused directly by an electrode but
resolved spontaneously with no delay in discharge. Authors
suggested that electrodes could be placed during periods of apnea
tominimize diaphragmatic movement if the procedure carried the
risk of pneumothorax. Cardiac arrhythmia is also a notable
serious complication from IRE due to the presence of high current
close to the heart. Ventricular bigeminy, ventricular tachycardia,
and atrial ﬁbrillation were reported by Ball et al and Thomson
et al.[43,44] According to the study, the most serious cardiac
rhythm disturbance occurred during the ablation of a very large
hepatic tumor which was directly beneath the diaphragm and
close to the inferior cardiac border.[43]
In conclusion, although IRE has been introduced in the clinical
arena within the past decade, it has successfully claimed its
valuable status in the ﬁeld of hepatic cancer treatment though it
possesses its own disadvantages as discussed above. In order to
systemically test and establish its safety and efﬁcacy for clinical
applications, more studies still need to be conducted.References
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